Core Insights - Immunome, Inc. is set to present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025, at 8:30 a.m. ET [1] - The company focuses on developing first-in-class and best-in-class targeted cancer therapies, with a strong emphasis on innovative therapeutics [3] Company Overview - Immunome is a clinical-stage targeted oncology company dedicated to improving outcomes for cancer patients through advanced therapies [3] - The company has a diverse pipeline, including varegacestat in Phase 3 for desmoid tumors, IM-1021 in Phase 1 targeting ROR1, and IM-3050, a FAP-targeted radioligand that has received IND clearance [3] - Additional preclinical ADCs in the pipeline include IM-1617, IM-1335, and IM-1340, targeting undisclosed markers in various solid tumors [3] Recent Developments - Immunome recently presented preclinical data indicating that its proprietary ADC payload HC74 can overcome multiple mechanisms of ADC resistance, enhancing the efficacy of its therapies [5] - The company has granted inducement awards of stock options to new employees, totaling 69,000 shares on October 1, 2025, and 117,000 shares on September 2, 2025, under Nasdaq Listing Rule 5635(c)(4) [6][7]

Core Viewpoint - Immunome, Inc. is focused on developing innovative targeted cancer therapies and will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025 [1][2]. Company Overview - Immunome is a clinical-stage biotechnology company dedicated to creating first-in-class and best-in-class targeted therapies for cancer patients [3]. - The company has a portfolio that includes advanced pipeline programs such as varegacestat, IM-1021, and IM-3050, with various stages of clinical trials [3]. Pipeline and Research - The most advanced programs include: - Varegacestat (formerly AL102), a gamma secretase inhibitor in Phase 3 trials for desmoid tumors [3]. - IM-1021, a ROR1-targeted ADC currently in Phase 1 trials [3]. - IM-3050, a FAP-targeted radioligand that has recently received IND clearance [3]. - Immunome has also presented preclinical data indicating that its proprietary ADC payload HC74 can overcome multiple mechanisms of ADC resistance [5]. Inducement Grants - On October 1, 2025, Immunome granted inducement awards consisting of non-statutory stock options for 69,000 shares to five new employees [6]. - Additionally, on September 2, 2025, the company granted inducement awards for 117,000 shares to eight new employees [7].

Core Viewpoint - Whitehawk Therapeutics Inc. announced a multi-year collaboration with Tempus AI aimed at advancing biomarker-driven research, which has influenced its stock performance despite a recent drop in after-hours trading [2]. Group 1: Collaboration Details - The partnership with Tempus AI will utilize its proprietary real-world dataset to support the development of Whitehawk's oncology pipeline [2]. - The collaboration announcement gained traction on social media, indicating potential investor interest and market engagement [2]. Group 2: Recent Earnings Performance - Whitehawk reported a loss of $0.76 per share for the second quarter, missing expectations of a $0.09 gain, and reported no revenue for the quarter, falling short of the $60 million estimate [3]. - The next earnings report is scheduled for November 15 [3]. Group 3: Stock Performance - Whitehawk's shares have gained 21.96% over the past year and risen 33.85% in the past month, although the stock is down 17.41% year-to-date in 2025 [4]. - The market capitalization of Whitehawk is $122.42 million, with shares trading between $1.39 and $3.81 over the past year and an average daily trading volume of about 118,820 shares [4]. Group 4: Stock Trend Analysis - Benzinga Edge Stock Rankings indicate that WHWK has a positive price trend across all time frames, suggesting favorable market sentiment [5].

Core Insights - AlphaTON Capital has been recognized by Nasdaq for its innovative approach to funding cancer research through asset tokenization, marking a significant milestone in the intersection of digital assets and medical research funding [3][9] - The partnership with Cyncado Therapeutics aims to revolutionize cancer treatment financing by creating a transparent and accessible investment mechanism that connects global investors with oncology research programs [4][5] Company Overview - AlphaTON Capital is a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, while also engaging in blockchain-based healthcare financing [3][11] - The company implements a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders [11] Innovative Funding Model - The collaboration with Cyncado Therapeutics addresses critical challenges in cancer research funding, including enhanced liquidity, transparent allocation of funds, reduced barriers to entry for investors, and accelerated research timelines [7][8] - Tokenized assets provide greater flexibility and market access, allowing for a broader audience participation in medical innovation [7] Market Recognition and Future Plans - The recognition from Nasdaq signals growing institutional acceptance of tokenized assets in regulated markets, positioning AlphaTON Capital as a leader in the emerging institutional digital asset space [9] - The company plans to expand its tokenization initiative to additional therapeutic areas and research institutions, with several partnerships currently in development [10]

Core Insights - AlphaTON Capital Corp is at the forefront of the decentralized science (DeSci) movement, leveraging its TON infrastructure to enhance cancer research, particularly in mesothelioma through a non-binding letter of intent for tokenization of single-indication economics for TT-4 [1][2][4] Company Overview - AlphaTON is the only Nasdaq-listed company that operates a strategic TON token treasury while advancing first-in-class immunotherapy assets, integrating decentralized science principles with medical research funding [2][3] - The company aims to democratize access to cancer research and align global stakeholders with patient outcomes through innovative financing mechanisms [4][8] Clinical Development - Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, is preparing for the clinical start-up of TT-4, an oral A2B receptor antagonist, with first-patient dosing expected in Q1 2026 [5][14] - The initial study will focus on safety dose-escalation in solid tumor patients, followed by a larger mesothelioma-focused study at major U.S. cancer centers [5] Scientific Validation - Preclinical data for TT-4 shows promising results, including 90% tumor growth inhibition in murine models when combined with anti-PD-1 therapy and 60% complete responses [7][6] - The drug's mechanism aims to neutralize immune suppression and enhance anti-tumor responses, demonstrating superior activity compared to existing checkpoint inhibitors [7] Decentralized Science Movement - The DeSci movement seeks to transform how scientific research is funded and shared, with AlphaTON's tokenization initiative positioning it as a leader in this space [8][9] - The company aims to enhance transparency in clinical development and create direct value alignment between research supporters and therapeutic success [13] Strategic Vision - AlphaTON's business model integrates its validator operations, ecosystem investments, and therapeutic programs to create synergies that accelerate the path from laboratory to patient [9][10] - The exploratory LOI for tokenization is designed to preserve traditional therapeutic development pathways while exploring innovative funding models [10]

Core Insights - The Oncology Institute (NASDAQ: TOI) is participating in the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025, with a presentation scheduled at 11:00am ET [1][2]. Company Overview - Founded in 2007, The Oncology Institute is focused on providing specialized, value-based cancer care in community settings, serving approximately 1.9 million patients [3]. - The company operates over 100 clinics and affiliate locations across five states, employing more than 180 clinicians [3].

Table of Contents As filed with the Securities and Exchange Commission on September 30, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KAZIA THERAPEUTICS LIMITED (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant ...

Core Insights - The Oncology Institute (TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care, emphasizing whole-person care [1][2][3] Partnership Overview - The collaboration aims to provide timely access to mental health services for cancer patients, addressing emotional and psychological challenges without waitlists [2][3] - Protocol Behavioral Health's approach ensures that mental health care is a core part of the treatment plan from the beginning [4] Patient Impact - Approximately 30% of cancer patients experience significant depression or anxiety, and behavioral health support is recognized as beneficial for nearly all patients [2] - The integration of behavioral health services is expected to improve treatment adherence, quality of life, and patient satisfaction [6] Operational Model - The partnership utilizes the Collaborative Care Model (CoCM), which integrates behavioral health managers and psychiatric providers into oncology care teams [5][6] - This model facilitates seamless coordination and personalized support for patients throughout their cancer journey [5][6] Company Background - The Oncology Institute, founded in 2007, provides specialized, value-based cancer care to approximately 1.9 million patients across multiple states [4] - Protocol Behavioral Health focuses on evidence-based mental health care tailored to the unique needs of cancer patients [5]

Company Overview - Lite Strategy Inc. (NASDAQ: LITS), previously known as MEI Pharma, Inc. and traded under the ticker "MEIP," was focused on oncology with two drug candidates, vorucliclib and ME-144, which were aimed at oncology combination therapies [1]. Analyst Background - The article includes a brief background of Myriam Hernandez Alvarez, who holds multiple degrees in engineering, computer science, business management, and computer applications, indicating a strong academic foundation relevant to the analysis [1]. Disclosure Information - The article contains disclosures stating that the analyst has no stock or derivative positions in the companies mentioned and has no plans to initiate any such positions within the next 72 hours [2]. - It is noted that the opinions expressed are independent and not influenced by any business relationships with the companies discussed [2].

Company Overview - Delcath Systems, Inc. is a medical technology company focused on oncology, specifically developing therapies for primary and metastatic liver cancers [1] - The main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure [1] - Delcath operates in a competitive landscape with peers including Interpace Biosciences, EOM Pharmaceuticals Holdings, Aeterna Zentaris, and Rennova Health [1] Financial Performance - Delcath's Return on Invested Capital (ROIC) is 3.58%, which is lower than its Weighted Average Cost of Capital (WACC) of 7.61%, indicating insufficient returns to cover capital costs [2] - In comparison, Interpace Biosciences has a positive ROIC of 84.16% with a WACC of 9.41%, resulting in a favorable ROIC to WACC ratio of 8.94, suggesting better capital efficiency than Delcath [3] - EOM Pharmaceuticals Holdings exhibits an impressive ROIC of 1,140.12% and a WACC of 16.82%, leading to a ROIC to WACC ratio of 67.77, indicating strong capital efficiency and growth potential [4] - Aeterna Zentaris and Rennova Health both report negative ROICs, highlighting challenges in generating sufficient returns on invested capital [4]